MARIUS, Trøseid, JR ARRIBAS, Assoumou LAMBERT, Holten ALEKSANDER, Poissy JULIEN, Terzić VIDA, Mazzaferri FULVIA, Jesús RODRÍGUEZ-BAÑO, Eustace JOE, Hites MAYA, Joannidis MICHAEL, Paiva JOSÉ, Reuter JEAN, Püntmann ISABEL, Thale Dawn PATRICK-BROWN, Elin WESTERHEIM, Katerina NEZVALOVA-HENRIKSEN, Beniguel LYDIE, Dahl TUVA and Costagliola DOMINIQUE. Efficacy and Safety of Baricitinib for the Treatment of Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Trial. Critical Care. LONDON: BMC, vol. 27, No 1, p. 1-15. ISSN 1364-8535. doi:10.1186/s13054-022-04205-8. 2023. |
Other formats:
BibTeX
LaTeX
RIS
@article{2233339, author = {Marius, Trøseid and Arribas, JR and Lambert, Assoumou and Aleksander, Holten and Julien, Poissy and Vida, Terzić and Fulvia, Mazzaferri and RodríguezandBaño, Jesús and Joe, Eustace and Maya, Hites and Michael, Joannidis and José, Paiva and Jean, Reuter and Isabel, Püntmann and PatrickandBrown, Thale Dawn and Westerheim, Elin and NezvalovaandHenriksen, Katerina and Lydie, Beniguel and Tuva, Dahl and Dominique, Costagliola}, article_location = {LONDON}, article_number = {1}, doi = {http://dx.doi.org/10.1186/s13054-022-04205-8}, keywords = {COVID-19; immunomodulator; safety; baricitinib; JAK inhibitor}, language = {eng}, issn = {1364-8535}, journal = {Critical Care}, title = {Efficacy and Safety of Baricitinib for the Treatment of Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Trial.}, url = {https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4172086}, volume = {27}, year = {2023} }
TY - JOUR ID - 2233339 AU - Marius, Trøseid - Arribas, JR - Lambert, Assoumou - Aleksander, Holten - Julien, Poissy - Vida, Terzić - Fulvia, Mazzaferri - Rodríguez-Baño, Jesús - Joe, Eustace - Maya, Hites - Michael, Joannidis - José, Paiva - Jean, Reuter - Isabel, Püntmann - Patrick-Brown, Thale Dawn - Westerheim, Elin - Nezvalova-Henriksen, Katerina - Lydie, Beniguel - Tuva, Dahl - Dominique, Costagliola PY - 2023 TI - Efficacy and Safety of Baricitinib for the Treatment of Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Trial. JF - Critical Care VL - 27 IS - 1 SP - 1-15 EP - 1-15 PB - BMC SN - 13648535 KW - COVID-19 KW - immunomodulator KW - safety KW - baricitinib KW - JAK inhibitor UR - https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4172086 N2 - Background: The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown efficacy in mixed populations of hospitalised participants with COVID-19. Bari-SolidAct is the first trial in the investigator-initiated, adaptive platform trial EU-SolidAct, and is a multinational, phase 3, randomised, double-blind, placebo-controlled trial of baricitinib in hospitalised patients with confirmed SARS-CoV-2 infection. We aimed to evaluate the efficacy and safety of baricitinib plus standard of care in hospitalised adults with severe or critical COVID-19. ER -
MARIUS, Trøseid, JR ARRIBAS, Assoumou LAMBERT, Holten ALEKSANDER, Poissy JULIEN, Terzi$\backslash$'c VIDA, Mazzaferri FULVIA, Jesús RODRÍGUEZ-BAÑO, Eustace JOE, Hites MAYA, Joannidis MICHAEL, Paiva JOSÉ, Reuter JEAN, Püntmann ISABEL, Thale Dawn PATRICK-BROWN, Elin WESTERHEIM, Katerina NEZVALOVA-HENRIKSEN, Beniguel LYDIE, Dahl TUVA and Costagliola DOMINIQUE. Efficacy and Safety of Baricitinib for the Treatment of Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Trial. \textit{Critical Care}. LONDON: BMC, vol.~27, No~1, p.~1-15. ISSN~1364-8535. doi:10.1186/s13054-022-04205-8. 2023.
|